Oral Flurbiprofen Metabolic Ratio Assessment Using a Single-Point Dried Blood Spot

被引：23

作者：

Daali, Y. ^{[1
,2
]}

Samer, C. ^{[2
]}

Deglon, J. ^{[2
,3
]}

Thomas, A. ^{[2
,3
]}

Chabert, J.

Rebsamen, M. ^{[1
]}

Staub, C. ^{[2
,3
]}

Dayer, P. ^{[2
]}

Desmeules, J. ^{[2
]}

机构：

[1] Univ Hosp Geneva, Dept Lab Med, Geneva, Switzerland

[2] Univ Geneva, Swiss Ctr Appl Human Toxicol, Geneva, Switzerland

[3] CURML, Toxicol Unit, Geneva, Switzerland

来源：

CLINICAL PHARMACOLOGY & THERAPEUTICS | 2012年 / 91卷 / 03期

关键词：

CYP2C9; ACTIVITY; PHARMACOKINETIC CONSIDERATIONS; KAROLINSKA COCKTAIL; INDUCTION; TOLBUTAMIDE; GENOTYPE; ENZYMES; PLASMA; MARKER; CYP450;

D O I：

10.1038/clpt.2011.247

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

We investigated whether a single blood measurement using the minimally invasive technique of a finger prick to draw a blood sample of 5 mu l (to yield a dried blood spot (DBS)) is suitable for the assessment of flurbiprofen (FLB) metabolic ratio (MR). Ten healthy volunteers who had been genotyped for CYP2C9 were recruited as subjects. They received FLB alone in session 1 and FLB with fluconazole in session 2. In session 3, the subjects were pretreated for 4 days with rifampicin and received FLB with the last dose of rifampicin on days. Plasma and DBS samples were obtained between 0 and 8 h after FLB administration, and urine was collected during the 8 h after administration. The pharmacokinetic profiles of the drugs were comparable in DBS and plasma. FLB's apparent clearance values decreased by 35% in plasma and DBS during session 2 and increased by 75% in plasma and by 30% in DBS during session 3. Good correlations were observed between MRs calculated from urine, plasma, and DBS samples.

引用

页码：489 / 496

页数：8

共 31 条

[1]

Boer T., 2011, BIOMED CHROMATOGR, V25, P1112

[2]

Phenytoin metabolic ratio:: a putative marker of CYP2C9 activity in vivo [J].

Caraco, Y ;

Muszkat, M ;

Wood, AJJ .

PHARMACOGENETICS, 2001, 11 (07) :587-596

[3]

Dried blood spot measurement: application in tacrolimus monitoring using limited sampling strategy and abbreviated AUC estimation [J].

Cheung, Chi Yuen ;

van der Heijden, Jaques ;

Hoogtanders, Karin ;

Christiaans, Maarten ;

Liu, Yan Lun ;

Chan, Yiu Han ;

Choi, Koon Shing ;

van de Plas, Afke ;

Shek, Chi Chung ;

Chau, Ka Foon ;

Li, Chun Sang ;

van Hooff, Johannes ;

Stolk, Leo .

TRANSPLANT INTERNATIONAL, 2008, 21 (02) :140-145

[4]

The Karolinska cocktail for phenotyping of five human cytochrome P450 enzymes [J].

Christensen, M ;

Andersson, K ;

Dalén, P ;

Mirghani, RA ;

Muirhead, GJ ;

Nordmark, A ;

Tybring, G ;

Wahlberg, A ;

Yasar, Ü ;

Bertilsson, L .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (06) :517-528

[5]

Development and validation of a chemical hydrolysis method for dextromethorphan and dextrophan determination in urine samples: Application to the assessment of CYP2D6 activity in fibromyalgia patients [J].

Daali, Y. ;

Cherkaoui, S. ;

Doffey-Lazeyras, F. ;

Dayer, P. ;

Desmeules, J. A. .

JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2008, 861 (01) :56-63

[6]

CLINICAL PHARMACOKINETICS OF FLURBIPROFEN AND ITS ENANTIOMERS [J].

DAVIES, NM .

CLINICAL PHARMACOKINETICS, 1995, 28 (02) :100-114

[7]

Automated system for on-line desorption of dried blood spots applied to LC/MS/MS pharmacokinetic study of flurbiprofen and its metabolite [J].

Deglon, Julien ;

Thomas, Aurelien ;

Daali, Youssef ;

Lauer, Estelle ;

Samer, Caroline ;

Desmeules, Jules ;

Dayer, Pierre ;

Mangin, Patrice ;

Staub, Christian .

JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2011, 54 (02) :359-367

[8]

Use of the dried blood spot sampling process coupled with fast gas chromatography and negative-ion chemical ionization tandem mass spectrometry: application to fluoxetine, norfluoxetine, reboxetine, and paroxetine analysis [J].

Deglon, Julien ;

Lauer, Estelle ;

Thomas, Aurelien ;

Mangin, Patrice ;

Staub, Christian .

ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2010, 396 (07) :2523-2532

[9]

A Phenotype-Genotype Approach to Predicting CYP450 and P-Glycoprotein Drug Interactions With the Mixed Inhibitor/Inducer Tipranavir/Ritonavir [J].

Dumond, J. B. ;

Vourvahis, M. ;

Rezk, N. L. ;

Patterson, K. B. ;

Tien, H-C ;

White, N. ;

Jennings, S. H. ;

Choi, S. O. ;

Li, J. ;

Wagner, M. J. ;

La-Beck, N. M. ;

Drulak, M. ;

Sabo, J. P. ;

Castles, M. A. ;

MacGregor, T. R. ;

Kashuba, A. D. M. .

CLINICAL PHARMACOLOGY & THERAPEUTICS, 2010, 87 (06) :735-742

[10]

Dried Blood Spot Methods in Therapeutic Drug Monitoring: Methods, Assays, and Pitfalls [J].

Edelbroek, Peter M. ;

van der Heijden, Jacques ;

Stolk, Leo M. L. .

THERAPEUTIC DRUG MONITORING, 2009, 31 (03) :327-336

← 1 2 3 4 →